Skip to content

Study on Obesity management in non diabetics

Evaluation of effectiveness of oral Teneligliptin on obesity, lipid profile, Insulin resistance & Quality of life among obesity and overweight participants - OLIQ

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/02/023329
Enrollment
150
Registered
2020-02-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E660- Obesity due to excess calories

Interventions

Intervention1: Weight reduction: Teneligliptin and Low crb diet physical exercise Intervention2: Low carbohydrate diet & Physical ecercise: low carbohydrate diet (48 weeks) which Includes: Natural pro

Sponsors

Self financed
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Body mass index (BMI) >= 30 kg/m2 or >= 27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): Mild to Moderate Hypertension Dyslipidemia History of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion criteria: Subjects are excluded from the study if any of the following criteria apply: 1.Glycemic related: HbA1C >= 48 mmol/mol (6.5%) at screening Treatment with glucose lowering agent (s) within 90 days before screening Treatment with a DPP-4 inhibitors or GLP-1 receptor agonists within 180 days of before screening. 2.Obesity related: A self-reported change in body weight > 5 kg (11 lbs) within 90 days before screening irrespective of medical records Treatment with any medication for the indication of obesity within the past 90 days before screening Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: liposuction and/or abdominoplasty, if performed > 1 year before screening lap banding, if the band has been removed > 1 year before screening Intragastric balloon, if the balloon has been removed > 1 year before screening Duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening Gastrointestinal surgeries that induces mal absorption Indication of liver diseases (elevated ALT/AST or ALP) History of pancreatitis Uncontrolled thyroid disease (TSH > 6.0 mIU/L or Severe Hypertension Severe Obstructive sleep apnoea or cardiovascular disease Psychological related: History of major depressive disorder within 2 years before screening Diagnosis of other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder) A Patient Health Questionnaire-9 (PHQ-9) score of >= 15 at screening A lifetime history of a suicidal attempt Suicidal behavior within 30 days before screening Others: Pregnant / lactating women Patients on assistance of use of contraceptive pills Patients receiving treatment with systemic corticosteroids

Design outcomes

Primary

MeasureTime frame
Reduction of Body weight 10-15 % from the baseline. Improvement of Blood pressure Improvement of Lipid levelsTimepoint: within one year

Secondary

MeasureTime frame
Improvement of weight related commodities such as Improvement of Blood pressure Improvement of Lipid levelsTimepoint: Within one year

Countries

India

Contacts

Public ContactRanakishor Pelluri

SRIHER chennai

vanithak9@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026